SEARCH:   Advanced

Blood, Vol. 106, Issue 4, 1189-1198, August 15, 2005 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Global approach to the diagnosis of leukemia using gene expression profiling Blood Haferlach et al. 106: 1189 Supplemental materials for: Haferlach et al, Vol. 106, Issue 4, 1189-1198 Files in this Data Supplement: Table S1. Correlation of gene expression as assessed by microarray and RT-PCR experiments (PDF, 191 KB) - Results from the one-versus-all comparison are given. Table S2. Supporting gene list c13 OVA (PDF, 214 KB) - Tables S3-S6. Additional confusion matrices (PDF, 127 KB) - Table S3: Confusion matrix for 13 subtypes as determined by 10-fold cross-validation including “AML normal” only. The matrix shows the predicted class as determined after 10 runs of SVM-based classifications. Accuracy: 96.5% Table S4. Confusion matrix for 13 subtypes as determined by 10-fold cross-validation including “AML other” only. The matrix shows the predicted class as determined after 10 runs of SVM-based classifications. Accuracy: 93.3% Table S5. Confusion matrix for 14 subtypes as determined by 10-fold cross-validation including both “AML normal” and “AML other.” The matrix shows the predicted class as determined after 10 runs of SVM-based classifications. Accuracy: 85.7% Table S6. Confusion matrix for subtypes “AML normal” and “AML other” as determined by 10-fold cross-validation. The matrix shows the predicted class as determined after 10 runs of SVM-based classifications. Accuracy: 73.7% Figure S1. Overall survival in cytogenetically defined subgroups of AML (PDF, 50 KB) - Patients analyzed in the present microarray study are shown left side. For comparison patients from a previous expanded analysis of our laboratory are shown on the right side. The respective survival differences are similar in both cohorts demonstrating that the microarray cohort is representative. Patients with complex aberrant karyotypes and those with AML and t(11q23)/MLL have the worst prognosis, patients with AML and t(15;17), t(8;21), or inv(16) have a relatively good prognosis. Importantly, there is no difference with regard to prognosis between patients with a normal karyotype and those with other karyotype (ie, those not in the before-mentioned subgroups). Figure S2. Comparisons of gene expression assessed by both microarray and Micro Fluidic Cards (MFC) (PDF, 49 KB) - Document S1. Supplemental information on methods and results (PDF, 100 KB) This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020